192 related articles for article (PubMed ID: 15482168)
1. Peginterferon-alpha(2b) and ribavirin.
Ahn J; Flamm S
Expert Rev Anti Infect Ther; 2004 Feb; 2(1):17-25. PubMed ID: 15482168
[TBL] [Abstract][Full Text] [Related]
2. Pegylated interferon with ribavirin therapy for chronic infection with the hepatitis C virus.
Foster GR
Expert Opin Pharmacother; 2003 May; 4(5):685-91. PubMed ID: 12739994
[TBL] [Abstract][Full Text] [Related]
3. Catatonia associated with pegylated interferon-α 2b and ribavirin for hepatitis C.
Quinn D; Kuchler E; Deming P; Arora S
Psychosomatics; 2012; 53(4):400-1. PubMed ID: 22748752
[No Abstract] [Full Text] [Related]
4. Treatment of chronic hepatitis C infection with peginterferons plus ribavirin.
Fried MW; Hadziyannis SJ
Semin Liver Dis; 2004; 24 Suppl 2():47-54. PubMed ID: 15346246
[TBL] [Abstract][Full Text] [Related]
5. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.
Shepherd J; Brodin H; Cave C; Waugh N; Price A; Gabbay J
Health Technol Assess; 2004 Oct; 8(39):iii-iv, 1-125. PubMed ID: 15461877
[TBL] [Abstract][Full Text] [Related]
6. Major depressive episode with psychotic features induced by pegylated interferon-alpha-2b and ribavirin treatment.
Sockalingam S; Balderson K
Int Clin Psychopharmacol; 2005 Sep; 20(5):289-90. PubMed ID: 16096520
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the Safety Profiles of Pegylated Interferon α-2a and α-2b Administered in Combination with Ribavirin for Chronic Hepatitis C Infection: A Real-World Retrospective Cohort Study.
Ide K; Sato I; Imai T; Hawke P; Yamada H; Kawasaki Y; Masaki N
Biol Pharm Bull; 2016 Dec; 39(12):2060-2065. PubMed ID: 27645378
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis C virus therapy to date.
Foster G; Mathurin P
Antivir Ther; 2008; 13 Suppl 1():3-8. PubMed ID: 18432157
[TBL] [Abstract][Full Text] [Related]
9. Characteristics of hepatitis C treatment with pegylated interferons and ribavirin.
Jiménez-Méndez R; Castañeda-Hernández G
Ann Hepatol; 2010; 9 Suppl():61-4. PubMed ID: 20713998
[TBL] [Abstract][Full Text] [Related]
10. Predicting early and sustained virological responses in prior nonresponders to pegylated interferon alpha-2b plus ribavirin retreated with peginterferon alpha-2a plus ribavirin and the benefit-risk ratio of retreatment.
Marcellin P; Craxi A; Brandao-Mello CE; Di Bisceglie AM; Andreone P; Freilich B; Rajender Reddy K; Olveira Martín A; Teuber G; Messinger D; Hooper G; Wat C; Tatsch F; Jensen DM
J Clin Gastroenterol; 2013 Oct; 47(9):786-93. PubMed ID: 23442834
[TBL] [Abstract][Full Text] [Related]
11. Interferon-alpha-2b plus ribavirin: a review of its use in the management of chronic hepatitis C.
Scott LJ; Perry CM
Drugs; 2002; 62(3):507-56. PubMed ID: 11827565
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of pegylated interferon alfa-2b and ribavirin combination therapy versus pegylated interferon monotherapy in hemodialysis patients: a comparison of 2 sequentially treated cohorts.
Tseng PL; Chen TC; Chien YS; Hung CH; Yen YH; Chang KC; Tsai MC; Lin MT; Lee CT; Shen CH; Hu TH
Am J Kidney Dis; 2013 Oct; 62(4):789-95. PubMed ID: 23746377
[TBL] [Abstract][Full Text] [Related]
13. Erythema Annulare Centrifugum in the Era of Triple Therapy With Boceprevir Plus Pegylated Interferon α-2b and Ribavirin for Hepatitis C Virus Infection.
di Meo N; Stinco G; Fadel M; Errichetti E; Trevisan G
J Cutan Med Surg; 2015; 19(3):203-4. PubMed ID: 26060126
[No Abstract] [Full Text] [Related]
14. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
Fried MW; Shiffman ML; Reddy KR; Smith C; Marinos G; Gonçales FL; Häussinger D; Diago M; Carosi G; Dhumeaux D; Craxi A; Lin A; Hoffman J; Yu J
N Engl J Med; 2002 Sep; 347(13):975-82. PubMed ID: 12324553
[TBL] [Abstract][Full Text] [Related]
15. A comparison of peginterferon α-2a and α-2b for treatment-naive patients with chronic hepatitis C virus: A meta-analysis of randomized trials.
Zhao S; Liu E; Chen P; Cheng D; Lu S; Yu Q; Wang Y; Wei K; Yang P
Clin Ther; 2010 Aug; 32(9):1565-77. PubMed ID: 20974315
[TBL] [Abstract][Full Text] [Related]
16. Pilot study of pegylated interferon alfa-2b and ribavirin for recurrent hepatitis C after liver transplantation.
Mukherjee S; Rogge J; Weaver L; Schafer DF
Transplant Proc; 2003 Dec; 35(8):3042-4. PubMed ID: 14697974
[TBL] [Abstract][Full Text] [Related]
17. Spotlight on peginterferon-alpha-2a (40 kD) plus ribavirin in the management of chronic hepatitis C mono-infection.
Keam SJ; Cvetković RS
BioDrugs; 2009; 23(1):63-8. PubMed ID: 19344193
[TBL] [Abstract][Full Text] [Related]
18. Pegylated interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4 in adolescents.
Al Ali J; Owayed S; Al-Qabandi W; Husain K; Hasan F
Ann Hepatol; 2010; 9(2):156-60. PubMed ID: 20526008
[TBL] [Abstract][Full Text] [Related]
19. Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications.
Wang YS; Youngster S; Grace M; Bausch J; Bordens R; Wyss DF
Adv Drug Deliv Rev; 2002 Jun; 54(4):547-70. PubMed ID: 12052714
[TBL] [Abstract][Full Text] [Related]
20. [Side-effects of pegylated interferon plus ribavirin therapy with or without protease inhibitor direct acting antiviral agents during treatment of chronic hepatitis C virus infection].
Hunyady B; Kovács B; Battyáni Z
Orv Hetil; 2011 Dec; 152(50):1997-2009. PubMed ID: 22112373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]